Rohinton Edalji

Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

Loren Lasko, Clarissa G. Jakob, Rohinton Edalji et al. · Nature · 2017 · 813 citations · Full text

Lineage-specific Tumours, Medicine, Immune Checkpoint Inhibitor +8

Structural Characterization of a Soluble Amyloid β-Peptide Oligomer

Liping Yu, Rohinton Edalji, John E. Harlan et al. · Biochemistry · 2009 · 352 citations

Structural Characterization, Alzheimer's Disease, Protein Assembly +15

NMR studies of [U-13C] cyclosporin A bound to cyclophilin: bound conformation and portions of cyclosporin involved in binding

Stephen W. Fesik, Robert T. Gampe, H. L. Eaton et al. · Biochemistry · 1991 · 192 citations

Discovery of <i>N</i>-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor

Keith F. McDaniel, Le Wang, Todd Soltwedel et al. · Journal of Medicinal Chemistry · 2017 · 133 citations · Full text

The small molecule ISRIB rescues the stability and activity of Vanishing White Matter Disease eIF2B mutant complexes

Yao Liang Wong, Lauren LeBon, Rohinton Edalji et al. · eLife · 2018 · 133 citations · Full text